Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score
- PMID: 33656803
- PMCID: PMC8120404
- DOI: 10.1002/ehf2.13251
Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score
Erratum in
-
Corrigendum.ESC Heart Fail. 2021 Oct;8(5):4364. doi: 10.1002/ehf2.13551. Epub 2021 Aug 2. ESC Heart Fail. 2021. PMID: 34342175 Free PMC article. No abstract available.
Abstract
Aims: Echocardiographic predictors of outcomes in heart failure with preserved ejection fraction (HFpEF) have not been systematically or independently validated. We aimed at identifying echocardiographic predictors of cardiovascular events in a large cohort of patients with HFpEF and to validate these in an independent large cohort.
Methods and results: We assessed the association between echocardiographic parameters and cardiovascular outcomes in 515 patients with heart failure with preserved left ventricular (LV) ejection fraction (>50%) in the MEtabolic Road to DIAstolic Heart Failure (MEDIA) multicentre study. We validated out findings in 286 patients from the Karolinska-Rennes Prospective Study of HFpEF (KaRen). After multiple adjustments including N-terminal pro-brain natriuretic peptide (NT-proBNP), the significant predictors of death or cardiovascular hospitalization were pulmonary arterial systolic pressure > 40 mmHg, respiratory variation in inferior vena cava diameter > 0.5, E/e' > 9, and lateral mitral annular s' < 7 cm/s. The combination of these four variables differentiated patients with <10% vs. >35% 1 year risk. Adding these four echocardiographic variables on top of clinical variables and NT-proBNP yielded significant net reclassification improvement (33.8%, P < 0.0001) and increase in C-index (5.3%, a change from 72.2% to 77.5%, P = 0.015) of similar magnitude as the addition of NT-proBNP on top of clinical variables alone. In the KaRen cohort, these four variables yielded a similar improvement in net reclassification improvement (22.3%, P = 0.014) and C-index (4.0%, P = 0.029).
Conclusions: Use of four simple echocardiographic parameters (within the MEDIA echo score), indicative of pulmonary hypertension, elevated central venous pressure, LV diastolic dysfunction, and LV long-axis systolic dysfunction, independently predicted prognosis and improved risk stratification additionally to clinical variables and NT-proBNP in HFpEF. This finding was validated in an independent cohort.
Keywords: Cardiac oedema; Cardiovascular diseases; Diastolic function; Echocardiography; Heart failure, diastolic; Preserved ejection fraction; Risk prediction.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
L.H.L. related to present manuscript: none; unrelated: research grants to author's institution and speaker's and/or consulting fees: AstraZeneca, Boehringer Ingelheim, Novartis, Bayer, Vifor Pharma, Boston Scientific, Sanofi, Myokardia, Pharmacosmos, Mundipharma, Orion Pharma, Merck/MSD, and Medscape. N.G. reports consulting fees, unrelated to this manuscript, from AstraZeneca, Boehringer Ingelheim, and Novartis. P.R. reports personal fees from Relypsa, Inc., a Vifor Pharma Group Company; AstraZeneca; Bayer; CVRx; Fresenius; Novartis; Grunenthal; Servier; Stealth Peptides; Vifor Fresenius Medical Care Renal Pharma; Idorsia; and Novo Nordisk, outside the submitted work; and cofounder: CardioRenal. F.Z. reports personal fees from AstraZeneca, Janssen, Bayer, Novartis, Boston Scientific, Resmed, Amgen, CVRx, General Electric, Boehringer, AstraZeneca, and Vifor Fresenius, outside the submitted work, and cofounder: CardioRenal.
Figures



Similar articles
-
Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.J Am Coll Cardiol. 2019 Dec 10;74(23):2858-2873. doi: 10.1016/j.jacc.2019.09.063. J Am Coll Cardiol. 2019. PMID: 31806129 Clinical Trial.
-
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.J Am Coll Cardiol. 2014 Feb 11;63(5):447-56. doi: 10.1016/j.jacc.2013.09.052. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24184245 Free PMC article. Clinical Trial.
-
Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.Mymensingh Med J. 2019 Apr;28(2):333-346. Mymensingh Med J. 2019. PMID: 31086148
-
Validation of the MEDIA echo score for the prognosis of heart failure with preserved ejection fraction.Heart Fail Rev. 2023 Mar;28(2):453-464. doi: 10.1007/s10741-022-10266-2. Epub 2022 Aug 30. Heart Fail Rev. 2023. PMID: 36038694 Review.
-
Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction.Eur J Heart Fail. 2024 Aug;26(8):1778-1787. doi: 10.1002/ejhf.3271. Epub 2024 May 7. Eur J Heart Fail. 2024. PMID: 38714362
Cited by
-
Prognostic models for patients suffering a heart failure with a preserved ejection fraction: a systematic review.ESC Heart Fail. 2024 Jun;11(3):1341-1351. doi: 10.1002/ehf2.14696. Epub 2024 Feb 6. ESC Heart Fail. 2024. PMID: 38318693 Free PMC article.
-
Prognosticators of All-Cause Mortality in Patients With Heart Failure With Preserved Ejection Fraction.Am J Cardiol. 2021 Nov 1;158:66-73. doi: 10.1016/j.amjcard.2021.07.044. Epub 2021 Aug 29. Am J Cardiol. 2021. PMID: 34465456 Free PMC article.
-
Interpreting Diastolic Dynamics and Evaluation through Echocardiography.Life (Basel). 2024 Sep 12;14(9):1156. doi: 10.3390/life14091156. Life (Basel). 2024. PMID: 39337939 Free PMC article. Review.
-
Risk Prediction Models and Novel Prognostic Factors for Heart Failure with Preserved Ejection Fraction: A Systematic and Comprehensive Review.Curr Pharm Des. 2023;29(25):1992-2008. doi: 10.2174/1381612829666230830105740. Curr Pharm Des. 2023. PMID: 37644795 Free PMC article.
-
Clinical value of a comprehensive clinical- and echocardiography-based risk score on predicting cardiovascular outcomes in ischemic heart failure patients with reduced ejection fraction.Clin Res Cardiol. 2025 May;114(5):541-556. doi: 10.1007/s00392-024-02399-1. Epub 2024 Mar 6. Clin Res Cardiol. 2025. PMID: 38446150 Free PMC article.
References
-
- Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population‐based study. N Engl J Med 2006; 355: 260–269. - PubMed
-
- Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite‐Moreira AF, Borbély A. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550. - PubMed
-
- Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165–193. - PubMed
-
- Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CS, Lancellotti P. How to diagnose heart failure with preserved ejection fraction: the HFA‐PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020; 22: 391–412. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials